The news: Virtual reality (VR)-based digital therapeutics (DTx) startup AppliedVR teamed up with noninvasive neuroimaging startup Kernel to study how brain activity changes after VR treatment for chronic pain.
How it works: AppliedVR and Kernel are conducting a clinical study examining how users’ brain activity changes before, during, and after the VR treatment.
RelieVRx is an FDA-approved VR treatment that helps patients manage their chronic pain through immersive virtual environments. RelieVRx engages patients in interventions like cognitive behavioral therapy, relaxation-response training, breathwork, mindfulness, and more.
Kernel’s FlowVR headset will be used in tandem with the VR treatment to measure different brain biomarkers associated with chronic pain. The headset uses functional near-infrared spectroscopy (fNIRS) to measure hemoglobin changes. These can indicate which parts of the brain may see higher blood flow in response to certain stimuli (like different parts of a VR program). Researchers can use this information to understand how changes in brain activity are correlated with changes in pain perception.
Why it’s worth watching: Hard clinical evidence proving that VR therapies can positively impact patients’ health is paramount for these DTx to make it to the mainstream.
More healthcare execs say they’re planning to deploy some type of VR tools within their organization:
This joint study is interesting, because unlike some previous clinical validation studies of VR DTx, this study digs into how patients are also affected during the treatment rather than just before and after. And it’s also directly measuring brain activity as opposed to other health data measurements that may be more indirect indicators of pain, like heart rate.